OncoMatch/Clinical Trials/NCT07389629
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Is NCT07389629 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies QL1706 Combined With Lenvatinib for iparomlimab and tuvonralimab.
Treatment: QL1706 Combined With Lenvatinib — Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score \>= 10).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage T1N0M0, T2N0M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: Chinese herbal medicine or immunomodulatory drugs with anti-tumor indications
Received Chinese herbal medicine or immunomodulatory drugs with anti-tumor indications within 14 days prior to the first use of the investigational drug
Cannot have received: systematic treatment (including thymosin, interferon, interleukin, except for local use to control pleural effusion)
Exception: local use to control pleural effusion
Perform systematic treatment (including thymosin, interferon, interleukin, except for local use to control pleural effusion)
Lab requirements
Blood counts
ANC >= 1.5 × 10^9/L (1500/mm^3); Platelet count >= 100 × 10^9/L (100000/mm^3); Hemoglobin >= 90 g/L
Liver function
Serum total bilirubin (TBIL) <= 1.5 × ULN; ALT and AST <= 2.5 × ULN; for subjects with liver metastases, AST and ALT <= 5 × ULN, serum albumin (ALB) >= 28g/L
Good organ function, screening laboratory test results meet the following criteria: (1) Hematology... (2) Liver... Coagulation function: INR and APTT <= 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07389629 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Chinese herbal medicine or immunomodulatory drugs with anti-tumor indications, systematic treatment (including thymosin, interferon, interleukin, except for local use to control pleural effusion) disqualifies patients from enrollment.
What disease stage is eligible?
Stage T1N0M0 or T2N0M0 is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages